TransMedics(TMDX) - 2025 Q4 - Annual Results

TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results Andover, Mass. – February 24, 2026 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights "We are very pleased with our fourth quarter and full year 2025 performance. These results reflect strong execu ...